Brokerages expect that Blueprint Medicines Corp (NASDAQ:BPMC) will report ($1.83) earnings per share for the current quarter, Zacks reports. Two analysts have provided estimates for Blueprint Medicines’ earnings, with the lowest EPS estimate coming in at ($2.02) and the highest estimate coming in at ($1.64). Blueprint Medicines reported earnings per share of ($0.62) during the same quarter last year, which would indicate a negative year-over-year growth rate of 195.2%. The firm is expected to issue its next quarterly earnings results on Wednesday, August 7th.
On average, analysts expect that Blueprint Medicines will report full-year earnings of ($7.76) per share for the current year, with EPS estimates ranging from ($8.55) to ($6.73). For the next fiscal year, analysts forecast that the company will report earnings of ($7.71) per share, with EPS estimates ranging from ($8.13) to ($7.26). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Blueprint Medicines.
Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.98) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.83) by ($0.15). Blueprint Medicines had a negative net margin of 603.88% and a negative return on equity of 59.26%. The firm had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.38 million. During the same period in the prior year, the company posted ($1.29) earnings per share. The company’s revenue for the quarter was down 23.2% on a year-over-year basis.
A number of equities research analysts have commented on BPMC shares. Zacks Investment Research raised shares of Blueprint Medicines from a “hold” rating to a “buy” rating and set a $88.00 price objective on the stock in a research report on Tuesday, April 30th. BidaskClub downgraded shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 16th. Cowen reissued a “buy” rating on shares of Blueprint Medicines in a research report on Tuesday, February 26th. Wedbush reissued an “outperform” rating on shares of Blueprint Medicines in a research report on Tuesday, February 26th. Finally, Morgan Stanley started coverage on shares of Blueprint Medicines in a research report on Wednesday, April 3rd. They issued an “overweight” rating and a $112.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Blueprint Medicines currently has a consensus rating of “Buy” and a consensus price target of $102.17.
Shares of NASDAQ:BPMC traded down $0.04 during trading hours on Friday, reaching $81.05. The stock had a trading volume of 4,470 shares, compared to its average volume of 398,508. Blueprint Medicines has a 1 year low of $44.58 and a 1 year high of $89.00. The company has a current ratio of 6.59, a quick ratio of 6.59 and a debt-to-equity ratio of 0.27. The company has a market cap of $3.96 billion, a PE ratio of -15.02 and a beta of 1.53.
In other news, insider Marion Dorsch sold 2,300 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $84.66, for a total value of $194,718.00. Following the completion of the transaction, the insider now owns 2,300 shares in the company, valued at approximately $194,718. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Ariel Hurley sold 415 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $85.55, for a total transaction of $35,503.25. Following the completion of the transaction, the insider now owns 415 shares of the company’s stock, valued at approximately $35,503.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 44,359 shares of company stock valued at $3,798,843. Company insiders own 3.15% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. LPL Financial LLC acquired a new stake in Blueprint Medicines during the 3rd quarter worth $411,000. Vanguard Group Inc. boosted its stake in Blueprint Medicines by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 3,735,390 shares of the biotechnology company’s stock worth $291,584,000 after purchasing an additional 111,972 shares during the period. Rhumbline Advisers boosted its stake in Blueprint Medicines by 46.1% during the 4th quarter. Rhumbline Advisers now owns 55,349 shares of the biotechnology company’s stock worth $2,984,000 after purchasing an additional 17,475 shares during the period. SG Americas Securities LLC boosted its stake in Blueprint Medicines by 485.3% during the 4th quarter. SG Americas Securities LLC now owns 9,962 shares of the biotechnology company’s stock worth $537,000 after purchasing an additional 8,260 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its stake in Blueprint Medicines by 2.5% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 24,671 shares of the biotechnology company’s stock worth $1,330,000 after purchasing an additional 595 shares during the period. Institutional investors and hedge funds own 93.93% of the company’s stock.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Recommended Story: What are the benefits of buying treasury bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.